Cullinan Therapeutics (CGEM) Net Equity Issued and Repurchased (2020 - 2024)

Cullinan Therapeutics' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $262.7 million for Q2 2024.

• In Q2 2024, Net Equity Issued and Repurchased changed N/A year-over-year to $262.7 million; the TTM figure through Sep 2025 stood at $262.7 million (changed 0.0% YoY), while the FY2024 annual figure was $262.7 million, up 14291.89% from the prior year.
• Net Equity Issued and Repurchased for Q2 2024 stood at $262.7 million, up from $1.8 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $262.7 million in Q2 2024, with the low at -$800000.0 in Q2 2022.
• The 5-year median for Net Equity Issued and Repurchased is $1.8 million (2023), against an average of $31.7 million.
• The sharpest annual moves came in 2021 and 2022: Net Equity Issued and Repurchased surged 237.75% in 2021, then retreated 12.1% in 2022.
• Cullinan Therapeutics' Net Equity Issued and Repurchased stood at $800000.0 in 2020, then soared by 237.75% to $2.7 million in 2021, then declined by 12.1% to $2.4 million in 2022, then fell by 23.16% to $1.8 million in 2023, then surged by 14291.89% to $262.7 million in 2024.
• Business Quant data shows CGEM's Net Equity Issued and Repurchased at $262.7 million in Q2 2024, $1.8 million in Q1 2023, and $2.4 million in Q4 2022.